查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1412671

感染疾病疫苗市场：副产品、感染疾病和最终用户 - 全球预测 2024-2030

Infectious Vaccines Market by Product (Preventive Vaccine, Therapeutic Vaccine), Infectious Disease (Allergy, Cervical Cancer, DTP), End User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年感染疾病疫苗市场规模为300.1亿美元，2024年达318.3亿美元，2030年预计将达548.3亿美元，复合年增长率为8.98%。

全球感染疾病疫苗市场

主要市场统计
基准年[2023] 300.1亿美元
预测年份 [2024] 318.3亿美元
预测年份 [2030] 548.3亿美元
复合年增长率（%） 8.98%
传染病疫苗市场-IMG1

FPNV定位矩阵

FPNV定位矩阵对于评估感染疾病市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出资讯的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对感染疾病疫苗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵考察，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更资讯的决策并制定有效的策略，从而在市场上获得竞争优势。

该报告对以下几个方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场，并分析它们在成熟细分市场中的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-感染疾病疫苗市场规模及预测为何？

2-在感染疾病疫苗市场的预测期内，有哪些产品、细分市场、应用和领域需要考虑投资？

3-感染疾病疫苗市场的技术趋势和法律规范是什么？

4-感染疾病疫苗市场主要厂商的市场占有率是多少？

5-进入感染疾病疫苗市场合适的型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 爱滋病毒、癌症和糖尿病等慢性病的盛行率很高
      • 政府重点进行疫情防治工作
      • 消费者健康意识和支出不断提高
    • 抑制因素
      • 疫苗生产高成本、工期长
    • 机会
      • 增加公营和私营部门对研发的投资
      • 新型感染疾病疫苗简介
    • 任务
      • 疫苗的潜在副作用和不利事件
  • 市场区隔分析
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章感染疾病疫苗市场：副产品

  • 预防性疫苗
  • 治疗性疫苗

第七章 依感染疾病的感染疾病疫苗市场

  • 过敏
  • 子宫颈癌
  • DTP
  • 肝炎
  • 流感
  • 脑膜炎奈瑟菌
  • MMR
  • 肺炎球菌
  • 小儿麻痹
  • 轮状病毒
  • 水痘

第八章感染疾病疫苗市场：依最终用户分类

  • 成人
  • 小儿科

第九章 北美、南美感染疾病疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区感染疾病疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东、非洲感染疾病疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析

第13章竞争产品组合

  • 主要公司简介
    • Abbott Laboratories
    • Astellas Pharma, Inc.
    • AstraZeneca PLC
    • Bavarian Nordic A/S
    • Bharat Biotech
    • Biological E Ltd.
    • CSL Limited
    • DAIICHI SANKYO COMPANY, LIMITED
    • Emergent BioSolutions Inc.
    • GlaxoSmithKline PLC
    • Incepta Vaccine, Ltd.
    • Johnson and Johnson Services Inc.
    • Lonza Group AG
    • Merck & Co., Inc.
    • Mitsubishi Tanabe Pharma Corporation
    • Novartis International AG
    • Novavax, Inc.
    • Pfizer, Inc.
    • Sanofi SA
    • Serum Institute of India Pvt., Ltd
    • Sinovac Biotech Ltd.
  • 主要产品系列

第十四章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-ED54C46E8F81

[183 Pages Report] The Infectious Vaccines Market size was estimated at USD 30.01 billion in 2023 and expected to reach USD 31.83 billion in 2024, at a CAGR 8.98% to reach USD 54.83 billion by 2030.

Global Infectious Vaccines Market

KEY MARKET STATISTICS
Base Year [2023] USD 30.01 billion
Estimated Year [2024] USD 31.83 billion
Forecast Year [2030] USD 54.83 billion
CAGR (%) 8.98%
Infectious Vaccines Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Infectious Vaccines Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Infectious Vaccines Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Infectious Vaccines Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astellas Pharma, Inc., AstraZeneca PLC, Bavarian Nordic A/S, Bharat Biotech, Biological E Ltd., CSL Limited, DAIICHI SANKYO COMPANY, LIMITED, Emergent BioSolutions Inc., GlaxoSmithKline PLC, Incepta Vaccine, Ltd., Johnson and Johnson Services Inc., Lonza Group AG, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis International AG, Novavax, Inc., Pfizer, Inc., Sanofi SA, Serum Institute of India Pvt., Ltd, and Sinovac Biotech Ltd..

Market Segmentation & Coverage

This research report categorizes the Infectious Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Preventive Vaccine
    • Therapeutic Vaccine
  • Infectious Disease
    • Allergy
    • Cervical Cancer
    • DTP
    • Hepatitis
    • Influenza
    • Meningococcal
    • MMR
    • Pneumococcal
    • Polio
    • Rotavirus
    • Varicella
  • End User
    • Adults
    • Pediatrics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Infectious Vaccines Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Infectious Vaccines Market?

3. What are the technology trends and regulatory frameworks in the Infectious Vaccines Market?

4. What is the market share of the leading vendors in the Infectious Vaccines Market?

5. Which modes and strategic moves are suitable for entering the Infectious Vaccines Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Infectious Vaccines Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. High prevalence of chronic diseases including HIV, cancer, diabetes
      • 5.1.1.2. Government focused activities to control epidemic diseases
      • 5.1.1.3. Rising consumer awareness and expenditure regarding health
    • 5.1.2. Restraints
      • 5.1.2.1. High costs and longer timelines required for vaccine production
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing investment by public & private sector for R&D endeavors
      • 5.1.3.2. Introduction of novel infectious vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Possibilities of vaccine side effects and adverse events
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Infectious Vaccines Market, by Product

  • 6.1. Introduction
  • 6.2. Preventive Vaccine
  • 6.3. Therapeutic Vaccine

7. Infectious Vaccines Market, by Infectious Disease

  • 7.1. Introduction
  • 7.2. Allergy
  • 7.3. Cervical Cancer
  • 7.4. DTP
  • 7.5. Hepatitis
  • 7.6. Influenza
  • 7.7. Meningococcal
  • 7.8. MMR
  • 7.9. Pneumococcal
  • 7.10. Polio
  • 7.11. Rotavirus
  • 7.12. Varicella

8. Infectious Vaccines Market, by End User

  • 8.1. Introduction
  • 8.2. Adults
  • 8.3. Pediatrics

9. Americas Infectious Vaccines Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Infectious Vaccines Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Infectious Vaccines Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. Astellas Pharma, Inc.
    • 13.1.3. AstraZeneca PLC
    • 13.1.4. Bavarian Nordic A/S
    • 13.1.5. Bharat Biotech
    • 13.1.6. Biological E Ltd.
    • 13.1.7. CSL Limited
    • 13.1.8. DAIICHI SANKYO COMPANY, LIMITED
    • 13.1.9. Emergent BioSolutions Inc.
    • 13.1.10. GlaxoSmithKline PLC
    • 13.1.11. Incepta Vaccine, Ltd.
    • 13.1.12. Johnson and Johnson Services Inc.
    • 13.1.13. Lonza Group AG
    • 13.1.14. Merck & Co., Inc.
    • 13.1.15. Mitsubishi Tanabe Pharma Corporation
    • 13.1.16. Novartis International AG
    • 13.1.17. Novavax, Inc.
    • 13.1.18. Pfizer, Inc.
    • 13.1.19. Sanofi SA
    • 13.1.20. Serum Institute of India Pvt., Ltd
    • 13.1.21. Sinovac Biotech Ltd.
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. INFECTIOUS VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. INFECTIOUS VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. INFECTIOUS VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. INFECTIOUS VACCINES MARKET DYNAMICS
  • FIGURE 7. INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2023 VS 2030 (%)
  • FIGURE 10. INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 12. INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. INFECTIOUS VACCINES MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. INFECTIOUS VACCINES MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. INFECTIOUS VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. INFECTIOUS VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 6. INFECTIOUS VACCINES MARKET SIZE, BY PREVENTIVE VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. INFECTIOUS VACCINES MARKET SIZE, BY THERAPEUTIC VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 9. INFECTIOUS VACCINES MARKET SIZE, BY ALLERGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. INFECTIOUS VACCINES MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. INFECTIOUS VACCINES MARKET SIZE, BY DTP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. INFECTIOUS VACCINES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. INFECTIOUS VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. INFECTIOUS VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. INFECTIOUS VACCINES MARKET SIZE, BY MMR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. INFECTIOUS VACCINES MARKET SIZE, BY PNEUMOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. INFECTIOUS VACCINES MARKET SIZE, BY POLIO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. INFECTIOUS VACCINES MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. INFECTIOUS VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. INFECTIOUS VACCINES MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. INFECTIOUS VACCINES MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES INFECTIOUS VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM INFECTIOUS VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. INFECTIOUS VACCINES MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 151. INFECTIOUS VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 152. INFECTIOUS VACCINES MARKET LICENSE & PRICING